Pages
- About Us
- Advocacy Groups for Patients with Cancer
- Cancer Trial and Treatment Resources for Clinicians
- Contact Us
- Industry | Why Partner with Us
- News | Cancer Research and Innovation
- Newsletter sign up
- Our Programs
- ASPiRATION Lung Cancer Study
- Cancer Screening Program (CaSP)
- Companion Studies (C2)
- Company Studies (C3)
- Genetic Cancer Risk in the Young (RisC) study
- Molecular Screening & Therapeutics (MoST) study
- MoST Core Studies (C1)
- MoST-LLy | Leukaemia & Lymphoma Subprogram
- SMOC+ (Multi-Organ Cancer Surveillance Study)
- Outsmarting Cancer, Together
- Patients & Families | Cancer Clinical Trials
- Privacy Policy
- Researchers | Why Work with Us
- Site Map
- Thank You
- The PrOSPeCT Program
News
- PrOSPeCT formally launches, bringing new hope to Australians with incurable or advanced cancers
- 7,000 patients reached via MoST
- Ground-breaking Australian research answers long-standing genetic mystery of why people develop rare hidden cancer
- New hope secured for Australians with LFS
- 5,000 patients reached on MoST
- SPORE grant to investigate leiomyosarcoma
- A Current Affair feature on MoST
- World Cancer Research Day 2022
- Rare Cancers Australia podcast series
- Presenting with Foundation Medicine at ESMO 2022
- We have entered into a collaboration agreement with Oncoshot
- $185 million investment to fast-track treatments for rare and ‘untreatable’ cancers
- APOS 2021 - DNA & Beyond - online event
- Pancreatic cancer program
- 2020 Masterclass Publications and webinar recordings
- ASPiRATION study - first patient enrolled
- Making a difference
- Masterclass webinar series - Demystifying the Molecular Tumour Board
- How cancer develops resistance to treatment
- A reflection on cancer
- Australian Government & Roche co-fund the ‘ASPiRATION’ lung cancer study
- Access to clinical trials crucial for Australians living with rare or uncommon cancers
- Ground-breaking trial brings personalised treatments to those with rare cancers
- Ground breaking trial